Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
1Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India
2Department of Otorhinolaryngology, All India Institute of Medical Sciences, New Delhi, India
© 2018 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case No. | Age (yr)/Sex | Clinical presentation | Imaging | Bronchoscopy | Clinical diagnosis | Pathology diagnosis | Management and outcome |
---|---|---|---|---|---|---|---|
1 | 13/M | Cough, hemoptysis × 3 mo | Intraluminal soft tissue mass of 3.5 cm in RMB | Mass lesion in RMB | Benign tumor | Leiomyoma | Excision; symptom-free at 5 yr |
2 | 18/M | Non-smoker; dyspnea, cough, fever × 8 mo | 1 cm endotracheal growth with calcification | Lower tracheal growth arising from postero- lateral wall of RMB | Benign tumor | Leiomyoma | Excision; symptom-free at 7 mo |
3 | 65/M | Smoker; hemoptysis SOB × 4 days | Intraluminal nodule of 0.5 cm in LMB | LMB nodule | Tuberculosis vs. malignancy | Leiomyoma | Excision; symptom-free at 4 mo |
4 | 28/F | Dyspnea, hemoptysis × 1 yr | RMB tumor of 3.5 cm with carina involvement and right lung collapse | Endobronchial lobulated growth occluding the RMB just distal to carina | Inflammatory myofibroblastic tumor | LMS | Radiotherapy 30 cycles/60 Gy, after which patient is asymptomatic for 8 mo |
5 | 57/F | Non-smoker; chest pain × 1 yr; h/o ATT | 5.1 cm mass in lower lobe of right lung | Intrabronchial growth | Lung carcinoma with bone and liver metastases | LMS | Chemotherapy 9 cycles; marked reduction in size at 9 mo |
Case No. | SMA | Desmin | SMMHC | Pan-CK | EMA | S-100 | HMB-45 | ALK-1 | EBV-LMP1 | MIB-1 LI (%) | Final diagnosis |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Diffuse + | Diffuse + | Diffuse + | Negative | Negative | Negative | Negative | Negative | Negative | 1–2 | LM |
2 | Diffuse + | Focal + | Diffuse + | Negative | Negative | Negative | Negative | Negative | Negative | 1–2 | LM |
3 | Diffuse + | Diffuse + | Diffuse + | Negative | Negative | Negative | Negative | Negative | Negative | 1 | LM |
4 | Focal + | Focal + | Focal + | Negative | Negative | Focal + | Negative | Negative | Negative | 8–10 | LMS |
Focal + | Diffuse + | Focal + | Negative | Negative | Negative | Negative | Negative | Negative | 8–10 | - | |
Negative | Focal + | Focal + | Negative | Negative | Focal + | Negative | Negative | Negative | 10 | ||
5 | Diffuse + | Focal + | Diffuse + | Negative | Focal + | Negative | Negative | Negative | Negative | 10 | LMS |
SMT, smooth muscle tumor; M, male; RMB, right main bronchus; SOB, shortness of breath; LMB, left main bronchus; F, female; LMS, leiomyosarcoma; h/o, history of; ATT, anti-tubercular treatment.
SMA, smooth muscle actin; SMMHC, smooth muscle myosin heavy chain; CK, cytokeratin; EMA, epithelial membrane antigen; HMB-45, human melanoma black 45; EBV, Epstein-Barr virus; LMP1, latent membrane protein; LM, leiomyoma; LMS, leiomyosarcoma.